Supernus Pharmaceuticals, Inc. (SUPN) Comparison with companies in other sectors?

Supernus Pharmaceuticals, Inc. has a share price of 55.99M. You can analyze Supernus Pharmaceuticals, Inc. (SUPN) competitors across different market sectors through stock heatmaps.

What are SUPN's NET and operating margins?

Supernus Pharmaceuticals, Inc. (SUPN) operating margin is around 0.11, and net profit margin is approximately 0.09 as of the latest reports.

In what way does SUPN's earnings per share (EPS) trend reflect its financial momentum?

Supernus Pharmaceuticals, Inc. (SUPN) EPS is 1.11 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Supernus Pharmaceuticals, Inc. is 30.25, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Supernus Pharmaceuticals, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Supernus Pharmaceuticals, Inc. like P/E which is 30.20, P/B which is 1.81, and PEG which is -1.93. Compare them with sector averages to evaluate if the stock is priced fairly.

Supernus Pharmaceuticals, Inc.

SUPN•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$33.58

$0.73(2.22%)

Fundamental Analysis of Supernus Pharmaceuticals, Inc. (SUPN)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.11

P/E Ratio

30.25

ROE

0.06%

Net Margin

0.09%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.88B

Shares OutstandingTotal number of shares issued

$55.99M

Book Value/ShareNet worth per share

$18.45

Revenue/ShareAnnual revenue per share

$11.96

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.11

Net MarginNet income as percentage of revenue

9.27%

Operating MarginOperating income as percentage of revenue

10.51%

ROEReturn on shareholders' equity

6.14%

ROAReturn on total assets

4.60%

ROCEReturn on capital employed

6.59%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.92

Cash/ShareCash and equivalents per share

$8.30

FCF YieldFree cash flow as percentage of market cap

8.69%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SUPNFinancial Ratios Analysis details for SUPN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SUPNSector Benchmarking details for SUPN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Supernus Pharmaceuticals, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Supernus Pharmaceuticals, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Supernus Pharmaceuticals, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Supernus Pharmaceuticals, Inc.

For Supernus Pharmaceuticals, Inc., essential financial indicators include EPS 1.11, PE 30.25, and ROE 0.06. These key ratios reveal insights into Supernus Pharmaceuticals, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Supernus Pharmaceuticals, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Supernus Pharmaceuticals, Inc.

Metrics like Net Margin 9.27% and ROA 4.60% shed light on how well Supernus Pharmaceuticals, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Supernus Pharmaceuticals, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Supernus Pharmaceuticals, Inc.

Using ratios such as P/B Ratio 1.81 and PEG Ratio -1.93, investors can assess whether Supernus Pharmaceuticals, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Supernus Pharmaceuticals, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Supernus Pharmaceuticals, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $2.92, provide a snapshot of Supernus Pharmaceuticals, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Supernus Pharmaceuticals, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Supernus Pharmaceuticals, Inc.

Investing in Supernus Pharmaceuticals, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Supernus Pharmaceuticals, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;